Accession Number:

AD1173939

Title:

Development of a New, More Effective Live-Attenuated Influenza Vaccine: An Essential Platform for Future Pandemic Protection

Descriptive Note:

[Technical Report, Final Report]

Corporate Author:

ROCHESTER UNIV NY

Personal Author(s):

Report Date:

2021-12-01

Pagination or Media Count:

66

Abstract:

Vaccination is the most cost-effective approach by which the spread of a pandemic influenza virus could be prevented, and severe disease reduced. However, current influenza vaccines have had poor efficacy. Thus, it is very important to develop a new and more effective live-attenuated influenza vaccine LAIV. We hypothesize that by understanding the molecular basis for the temperature sensitive ts and attenuated att phenotypes of LAIV, it will be possible to develop a new, more effective live-attenuated influenza vaccine that leverages LAIVs superior ability to protect against infection by diverse influenza viruses. Our goal is to develop a new and improved LAIV that has enhanced safety and efficacy, due to 1 a greater temperature sensitivity than current LAIVs, resulting in viral replication only in the lower temperatures of the nasal cavity and extreme upper airway and 2 high levels of virus gene expression but poor replication - resulting in abundant protein expression and immunogenicity but minimal production of infectious progeny virus.

Descriptors:

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

[A, Approved For Public Release]